Ayawilca Zinc Project Peru: Targeting Resource Growth in 2017
|
|
- Pierce Daniels
- 5 years ago
- Views:
Transcription
1 Ayawilca Zinc Project Peru: Targeting Resource Growth in 2017 PDAC Peru Day Presentation Dr Graham Carman Tinka Resources Limited March 6, 2017 OTC: TKRFF
2 Disclaimer This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. This presentation does not constitute or form a part of, and should not be construed as an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of Tinka, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Certain information in this presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively "forward-looking statements"). All statements, other than statements of historical fact are forward-looking statements. Forward-looking statements are based on the beliefs and expectations of Tinka as well as assumptions made by and information currently available to Tinka's management. Such statements reflect the current risks, uncertainties and assumptions related to certain factors including but not limited to, all costs varying significantly from estimates, production rates varying from estimates, changes in metal markets, changes in equity markets, the proposed use of net proceeds from private placements, availability and costs of financing needed in the future, equipment failure, unexpected geological conditions, imprecision in resource estimates or metal recoveries, ability to complete future drilling programs, drilling program results varying from expectations, delays in obtaining survey results, success of future development initiatives, the completion and implementation of a preliminary economic assessment, pre-feasibility or feasibility studies, competition, operating performance, environmental and safety risks, delays in obtaining or failure to obtain necessary permits and approvals from local authorities, community relations, and other development and operating risks. Should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein. Although Tinka believes that assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Except as may be required by applicable securities laws, Tinka disclaims any intent or obligation to update any forward-looking statement. The Mineral Resources disclosed in this company presentation were estimated by Mr. David Ross, P.Geo., an employee of Roscoe Postle Associates Inc. (RPA) and is independent of Tinka. The Zinc/Tin Mineral Resources were publicly released on May 25, 2016, while the Silver Resources were released on Feb 26, By virtue of his education and relevant experience, Mr. Ross is a "Qualified Person" for the purpose of National Instrument The Mineral Resources have been classified in accordance with CIM Definition Standards for Mineral Resources and Mineral Reserves. This presentation has been prepared, reviewed and verified by Dr. Graham Carman, Tinka s President and CEO and a Fellow of the Australasian Institute of Mining and Metallurgy, a qualified person as defined by NI
3 Company Highlights Ayawilca project in the Pasco region of Peru (also known as Colquipucro) was acquired by Tinka in 2005: Inferred Resources contain ~2.5 Billion pounds Zinc based on 27,000 metres drilled : 18.8 Million 8.2% Zinc Equivalent; and 5.4 Million 0.89% Tin Equivalent Initial metallurgy indicates zinc concentrate is good Tinka is fully-funded for its next growth phase: 10,000+ m step-out drill program commenced Feb 2017 Inicio de Actividades approved in February 2017 Modest valuation with lots of upside: Zinc price rose 60% in 2016 and tin price rose 45% ~C$70 million market capitalization ($0.34 /share) ~C$12 million cash at end of December 2016 Technical Team with past successes in Peru: ex Rio Tinto, Savage-Pasminco, Hochschild Inferred Resource: 2.45 billion pounds Zn * See slide 9 for complete mineral resource estimate details Peru Ayawilca 3
4 Capitalization and Zinc Peer Comparison Symbols: & OTC: TKRFF C$ Shares Issued: M Warrants: 27.2 M* 12.6 M at C$0.30 expire Nov M at C$0.45 expire May 2020 Options: Shares reserved: Fully diluted: 16.4 M 0.5 M M Market C$0.34/share: Cash 31 December 2016: C$70 M ~C$12 M Major shareholders: Sentient Group 22.4% International Finance Corp. 14.0% JP Morgan Asset Mgmt (UK) 7.3% Other institutions ~8% Management & directors ~2% * 15.7 M warrants held by IFC and 6.9 M warrants held by Sentient 4
5 Zinc Price Performance Zinc prices are up 64% YoY and fundamentals support higher prices Price performance driven by supply constraints and anticipated deficits LME zinc inventories are near 5 year lows 12 Month Metal Price Performance Zinc +64% Nickel +28% Copper +27% Tin +22% Silver +19% Gold +4% 5 08/02/ /02/ /03/ /03/ /04/ /04/ /05/ /05/ /05/ /06/ /06/ /07/ /07/ /08/ /08/ /09/ /09/ /10/ /10/ /10/ /11/ /11/ /12/ /12/ /01/ /01/ /02/2017
6 Management & Directors MANAGEMENT Graham Carman Alvaro Fernandez- Baca President & CEO, Director VP Exploration, Peru Geologist, PhD Lihir PNG, 25 years experience in mineral exploration, 15 yrs Peru experience, Ex Rio Tinto, Savage, Pasminco Geologist, P. Geo., APEGBC, Ex Hochschild, AQM Copper, Entrée Gold, Gitennes Javier Escudero HSEC Manager, Peru Health, Safety, Environment, Community & Permits. Ex Goldfields Nick Demare CFO, Director CPA, CA, officer/director, President of Chase Management Inc. Mariana Bermudez Corporate Secretary 19 years experience providing corporate secretarial, corporate governance and securities regulatory compliance services NON-EXECUTIVE DIRECTORS David Henstridge Founding director, geologist, 40 years worldwide experience Yanina Barilá Mary Little Sentient Group representative, MBA in finance from Buenos Aires Founder Mirasol Resources, Geologist, MBA, 15 years in Latin America 6
7 Peru A Mining Country Pro-mining country multiple world-class mines Lots of zinc in central Peru Ayawilca Project Antamina Mineral Rank in World 2015 Latin America 2015 Zinc 2nd 1st Copper 3rd 2nd Tin 3rd 1st Lead 4th 1st Silver 3rd 2nd Gold 5th 1st Las Bambas San Rafael * Only large mineral deposits shown 7
8 Peru Central Peru Mines Antamina: Largest current Copper/Zinc mine in Peru Cerro de Pasco: Largest historic Silver/Zinc mine in Peru Giant Ore Deposit 50 km 8
9 Ayawilca Mining Claims 150 km 2 mining claims (TK 100%) contiguous, no gaps Untested Targets Good Infrastructure Public roads Power nearby Water supplies Supportive local communities Silver resource Ayawilca zinc & tin resources 9
10 Ayawilca Zinc Zone Mineral resource updated May 2016 Ayawilca Zinc Zone Inferred Mineral Resources: 18.8 Mt grading 8.2% ZnEq Area Tonnage (Mt) ZnEq (%) Zn (%) Pb (%) In (g/t) Ag (g/t) Zn (Mlb) Pb (Mlb) In (000 kg) Ag (Moz) West Central , East Total , , Notes: 1. Mineral resource estimate at May 25, Base case highlighted ~ US$60/t NSR cut off (5% ZnEq). Metal price assumptions were US$1.00/lb Zn, US$500/kg In, US$20/oz Ag, US$1.00/lb Pb. Metal recovery assumptions were 90% Zn, 75% In, 50% Ag, and 75% Pb for the ZnEq calculation. 3. See NI report dated June 26, 2016, for details of resource estimates and assumptions 4. Inferred Mineral Resources have a great amount of uncertainty as to their existence, and as to their economic and legal feasibility. It cannot be assumed that all or any part of an Inferred Mineral Resource will ever be upgraded to a higher category. United States investors are cautioned not to assume that all or any part of Measured or Indicated Mineral Resources will ever be converted into Mineral Reserves. United States investors are also cautioned not to assume that all or any part of an Inferred Mineral Resource exists, or is economically or legally mineable. 10
11 Ayawilca Property Highlights One Property, Three Deposits: 1. Zinc Zone (Zn-In-Ag-Pb) Inferred Mineral Resource (May 2016): % ZnEq o 2.45 billion pounds of Zinc (1.1M tonnes) o 1,385,000 kilograms of Indium o 8.8 million ounces of Silver o 82 million pounds of Lead 2. Tin Zone (Sn-Ag-Cu) Inferred Mineral Resource (May 2016): % SnEq o 90 million pounds of Tin (41,000 tonnes) o 37 million pounds of Copper o 3.1 million ounces of Silver 3. Colquipucro Silver Oxide (Ag) Deposit Mineral Resource (higher grade lenses): g/t Ag (Indicated) and g/t Ag (Inferred) A17-56 Current Drill hole 11
12 Ayawilca: A Carbonate Replacement Deposit Zinc occur as mantos and chimneys in Pucará Group limestone Sulphides have replaced the carbonate host rock West Ayawilca Chimney Drill Hole From (m) To (m) Interval (m) Zinc (%) Lead (%) Silver (g/t) Indium (g/t) 4200mRL 4000mRL 3800mRL West Ayawilca open A including including and mRL Central Ayawilca East Ayawilca 4000mRL Sandstone 3800mRL Limestone 3600mRL Zinc Zone Tin Zone 500m Phyllite 3600mRL 12
13 Airborne Magnetic Anomaly Map (RTP) East Ayawilca West Ayawilca Zone 3 Central Ayawilca A17-56 South Ayawilca Priority Untested Targets 13
14 A17-56 drill hole (**released March **) First drill hole for 2017, massive sulphide mineralization found 400 metres from zinc resource, a new discovery 62.4 metres grading 5.6% Zinc from metres, including: 17.9 metres at 11.6% Zinc, including: 5.8 metres at 22.5 % Zinc And 5.2 metres grading 12.9 % Zinc from metres; Only sampled to 238 metres..more to come Qz Py Sph 14
15 Ayawilca District Schematic Cross Section Porphyry intrusion found at Los Pinos, 3 kilometres from Zinc Zone resource Large untested targets 15
16 Geochemistry Map Zinc in Soil Elevated zinc in soils over 10 sq km area A
17 Positive Initial Metallurgical Test Results West Ayawilca composite samples (two, grading 7% & 10% Zn): >98% recovery of Zn in first pass (rougher) 52% Zn concentrate grade produced in second pass (cleaner) concentrates Low manganese levels Indium reports to the zinc concentrate (350 ppm Indium average grade in con) 17
18 Proposed Exploration Program Milestone Zinc Zone Resource Upgrade Tin Zone Resource Silver Zone Review Geophysics Metallurgical tests Extend drill permits Drilling* PEA* * subject to drilling results/financing 18
19 Community & Environment Ongoing partnerships with three communities - employment and training Social engagement and sustainable development programs throughout the project area, fostering long-term relationships Working under IFC s guidance to implement best practices in Health, Safety, Environment and Community Training programs Animal health Road and drill platforms 19
20 Silver Mineral Resource - Colquipucro Class/Zone Tonnage (Mt) Ag (g/t) Ag (Moz) Indicated High Grade Lenses Low Grade Halo Total Indicated Inferred High Grade Lenses Low Grade Halo Total Inferred ,003 metres drilled in 45 holes ( ) Notes: : Resources estimated by Roscoe Postle Associates Inc. (RPA) of Toronto, Canada (news release of May 25, 2016). Mineral Resources are reported within a preliminary pit shell and above a cut-off grade of 60 g/t Ag for High Grade Lenses, and 15 g/t Ag for Low Grade Halo. The cut-off grade is based on a price of US$24/oz Ag. Refer to NI report dated June 29, 2016 for details of resource estimates and assumptions. 20
21 Summary One of the largest zinc discoveries in Peru in the last 20 years Existing Inferred zinc resource that contains 2.45 billion pounds of zinc Large untested targets provide potential for major mineral resource expansion Project located in Peru, a stable and mining friendly political jurisdiction Fully funded 10,000 metre drill program commenced February 2017 Zinc price forecast to increase further with continued Asian demand & tight supply Experienced Management Team and Board Supportive long term shareholders (Sentient, IFC, JP Morgan UK) Low valuation relative to zinc peers 21
22 Tinka Resources Limited Thank you! PDAC booth #2937 CORPORATE OFFICE Suite West Georgia St Vancouver, BC V6E 3V7 CANADA Ph: Fax: Graham Carman, President & CEO Rob Bruggeman, Investor Relations FOR MORE INFORMATION 22
2018: Growing & De-risking the Ayawilca Zinc Project in Peru
TSXV & BVL:TK OTCPK: TKRFF www.tinkaresources.com 2018: Growing & De-risking the Ayawilca Zinc Project in Peru Corporate Presentation May 2018 Disclaimer This presentation is not directed to, or intended
More informationCorporate Presentation January 2019
TSXV & BVL:TK OTCPK: TKRFF www.tinkaresources.com Corporate Presentation January 2019 Disclaimer This presentation is not directed to, or intended for distribution to or use by, any person or entity that
More informationJanuary A different kind of Zinc Explorer
January 2018 A different kind of Zinc Explorer Cautionary Statement This presentation contains certain statements that may be deemed "forward-looking statements". All statements in this presentation, other
More informationMutiny continues to hit high grade gold and copper intersections in latest Deflector drilling
Mutiny continues to hit high grade gold and copper intersections in latest Deflector drilling New Diamond drill results within the Deflector Deposit include: 3.3m @ 79g/t Au and 10.5% Cu from 62m in 12DD042
More informationMacmillan Pass Zinc Project: Growing an Already World-Class Asset
Macmillan Pass Zinc Project: Growing an Already World-Class Asset January 2018 Cautionary Statements The following statements are required by Canadian securities legislation: Forward-Looking Statements:
More informationRiesling Base Metal Project pxrf Soil Geochemistry
pxrf Soil Geochemistry Ken Harvey Non-executive Director Superior Resources Limited Riesling Located 280km NW Townsville & 17km SSW of Mount Surprise, North Queensland VMS (or Broken Hill) type deposit
More informationFirst Results Prospector Drilling Program
24 June 2008 Manager Company Announcements Company Announcements Office Australian Stock Exchange Limited Level 10, 20 Bond Street SYDNEY NSW 2000 ABN 42 082 593 235 Electronic delivery No of pages: 10
More informationDisclaimer. Matrix Metals Limited Presentation October
Matrix Metals Limited Presentation October 2008 Disclaimer The material used is this presentation is intended to be a summary of selected geological data, current and proposed activities, as well as resource
More information28 April 2017 ASX Code: COY. March 2017 Quarterly Activity Report
28 April 2017 ASX Code: COY The following report details the operating and corporate activities of Coppermoly Ltd (Coppermoly or the Company) for the quarter ended 31 March 2017 and to the date of this
More informationKihabe Zn, Pb, Ag Project Botswana
Kihabe Zn, Pb, Ag Project Botswana 8/800 Albany Highway East Victoria Park, WA 6101 www.mountburgess.com mtb@mountburgess.com ASX: MTB Kihabe 14.4Mt Resource* Nxuu 10.9Mt Resource* * See slide 5 for Resource
More informationExpanding Resources in the Caribbean
TSX.V: UGD Expanding Resources in the Caribbean CORPORATE PRESENTATION; September 2017 Forward Looking Statements Certain statements contained in this presentation, including statements regarding events
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationTRI ORIGIN MINERALS LTD
TRI ORIGIN MINERALS LTD Mines And Wines Conference September 2007 Woodlawn Zinc-Copper Projects ASX Code: TRO DISCLAIMER The Information contained in this presentation has been prepared using the information
More informationFor personal use only
ASX: VRX Diggers & Dealers August 2012 Bruce Maluish, Managing Director www.ventnorresources.com.au 1 Disclaimer & Competent Person This presentation was prepared with due care and attention and is current
More informationTSX: LUN OMX: LUMI Corpora Corpor t a e t Presen esen a t tion
TSX: LUN OMX: LUMI Corporate Presentation November 2013 Cautionary Statements Caution Regarding Forward Looking Statements This presentation contains forward looking statements. These forward looking statements
More informationPalmer Deposit 2018 Resource* INDICATED 5.2% Zn, 1.5% Cu, 30.8 g/t Ag, 0.3 g/t Au INFERRED 5.2% Zn, 1.0% Cu, 29.2 g/t Ag, 0.
14 m RW ZONE EAST upright limb Oxide Mineralization Palmer Deposit Long Section Looking North September 218 TSX-V:CEM steep overturned limb thrust faulted fold hinge SOUTH WALL ZONE I RW ZONE WEST 12 m
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationBISIE PROJECT UPDATE
Level 3, Gotthardstrasse 20, CH-6300, Zug, Switzerland Tel: +41 41 711 02 81 www.alphaminresources.com BISIE PROJECT UPDATE News Release 2014-10-27 VANCOUVER, CANADA October 27 th, 2014 Alphamin Resources
More informationHISTORICAL OVERVIEW OF GOLD COPPER MINERAL DISCOVERIES & MINE DEVELOPMENTS IN THE PHILIPPINES
15 10 05 120 125 120 125 15 10 05 HISTORICAL OVERVIEW OF GOLD COPPER MINERAL DISCOVERIES & MINE DEVELOPMENTS IN THE PHILIPPINES Spain China 3rd 1 th century North America Java 16 th 19 th century12 th
More informationAkie & Kechika Regional Projects. Akie Project: Zn Pb Ag Cardiac Creek Deposit Advanced Exploration
Akie & Kechika Regional Projects Akie Project: Zn Pb Ag Cardiac Creek Deposit Advanced Exploration May 2018 1 Legal Disclaimer This presentation contains forward looking statements; including in particular,
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationQ4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB
More informationSprott Investment Conference July 17-20, Booth 6
Sprott Investment Conference July 17-20, 2018 Booth 6 Forward Looking Statements This presentation contains forward-looking information that involves substantial known and unknown risks and uncertainties,
More informationObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationTSX Venture: RVV OTCQB: RVVTF
TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file. 2017 Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:
More informationPXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes
PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes Sébastien Bolze 1 ; Sophie Hallakou-Bozec 1 ; Michael Roden 2, 3,4 ; Julien Roux
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationOPEMISKA COPPER MINE COMPLEX. PORE: TSXV powerore.com
OPEMISKA COPPER MINE COMPLEX PORE: TSXV powerore.com FORWARD LOOKING STATEMENTS We are in the mineral exploration and development business. It is inherently risky, and all potential investors should be
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationMagSense Technology. For personal use only. Company Overview. A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer
MagSense Technology A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer Company Overview October 2017 ASX:IBX www.imagionbiosystems.com Disclaimer This presentation has been prepared
More informationLeading Cannabinoid Patient Care in Canada. Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF
Leading Cannabinoid Patient Care in Canada Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF Forward Looking Statements Except for historical information, this presentation contains forward-looking
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationA Zinc Play With A Bright Future. Corporate Presentation CSE: PSE FSE: PNX
A Zinc Play With A Bright Future Corporate Presentation CSE: PSE FSE: PNX Disclaimer The information contained in this presentation is provided by Pasinex Resources Limited. ( Pasinex ) for informational
More informationFor personal use only
Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by
More informationSCOUT DRILLING COMPLETED ON KELLERBERRIN URANIUM PROJECT
ASX ANNOUNCEMENT SCOUT DRILLING COMPLETED ON KELLERBERRIN URANIUM PROJECT ASX Code: MDX ABN: 28 106 866 442 Corporate Description Mindax's Mt Forrest Iron Project is progressing through feasibility with
More informationWorld leader in navigated, non-invasive brain stimulation therapy and diagnosis
World leader in navigated, non-invasive brain stimulation therapy and diagnosis Martin Jamieson CEO & Chairman of the Board Nexstim Plc Mikko Karvinen CFO Nexstim Plc Corporate Presentation, BioTrinity,
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationRevolutionizing how advanced heart disease is treated
LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More information(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health. December 2018
(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health December 2018 Safe Harbor Statement All statements in this presentation that are not based on historical fact are forward looking statements.
More informationFor personal use only
ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More informationMental Toronto Hydro
Mental Health @ Shirley Powell, Director, HR Planning, Systems & Rewards Benefits Canada s 2015 Healthy Outcomes Conference June 9-11, 2015 Niagara-on-the-Lake Company Overview Established in 1911 Largest
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationInvestor Presentation
Investor Presentation January 2012 Forward Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933,
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationFORM8-K HILLENBRAND,INC.
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015
More informationwhich has been used to help the treatment of epilepsy, seizures, alleviate neuropathic pain and muscular dystrophy.
News Release April 10, 2018, Kelowna, BC Marapharm Ventures Inc. To Introduce Organic CBD Health and Wellness Products To Be Featured In Its California Dispensary Marapharm Ventures Inc. (CSE: MDM) (OTCQX:
More informationBrisa Concessão Rodoviária. 1Q 2017 Traffic Update
Brisa Concessão Rodoviária 1Q 2017 Traffic Update 15 th May 2017 Disclaimer The information contained herein ( Information ) has been prepared by Brisa Concessão Rodoviária, S.A. ("BCR") and which, according
More informationE N H A N C IN G HE A LTH THRO U GH CANNABIS S CIENCE
I N V E S T O R P R E S E N TAT I O N Q 4 2 0 1 6 TM HEALTH THERAPEUTICS E N H A N C IN G HE A LTH THRO U GH CANNABIS S CIENCE T S X. V: E M H DISCLAIMER THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE
More informationNovo Nordisk has proposed to acquire Ablynx for up to per share in cash, consisting of upfront and 2.50 in Contingent Value Rights
Novo Nordisk has proposed to acquire Ablynx for up to 30.50 per share in cash, consisting of 28.00 upfront and 2.50 in Contingent Value Rights Proposal consists of upfront cash consideration of 28.00 per
More informationNewron announces 2018 financial results and provides outlook for 2019
Newron announces 2018 financial results and provides outlook for 2019 Milan, Italy, March 5, 2019 Newron Pharmaceuticals S.p.A. ( Newron ), a biopharmaceutical company focused on the development of novel
More informationEnel Américas 1Q 2018 results
Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation
More informationAerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More informationNot an Offer for Securities
Not an Offer for Securities This presentation has been prepared by REVA Medical, Inc. (REVA or the Company) solely for its use at presentations to be made by the Company. This presentation does not constitute
More informationSpiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria
Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria FINANCIAL TIMES INVESTING IN BULGARIA CONFERENCE Investment Opportunities in Bulgaria The Case of Solvay Sodi Spiros Nomikos CEO of Solvay Sodi
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationEvofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationDeveloping Xanamem for Alzheimer s Dementia
Developing Xanamem for Alzheimer s Dementia Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation March 2015 Forward Statements This presentation has been prepared by Actinogen Limited. ( Actinogen
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationImportant Notices. BASIS CPD Points PN/50971/1516/g
Chilli pepper results May 2016 1 Important Notices BASIS CPD Points PN/50971/1516/g This document is produced for information only and not in connection with any specific or proposed offer (the Offer )
More informationArgos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationDNI Metals - First 12 of 28 Diamond Core Assays Received; Including 34m Grading 5.63% Graphitic Carbon
DNI Metals - First 12 of 28 Diamond Core Assays Received; Including 34m Grading 5.63% Graphitic Carbon Toronto, Ontario--(Newsfile Corp. - December 7, 2017) - DNI Metals Inc. (DNI: CSE) (FSE: DG7N) (OTC
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationCavosonstat Phase 2 Trial Results. November 28 th, 2016
Phase 2 Trial Results November 28 th, 2016 Nivalis Therapeutics 2016 Agenda Introduction Mike Carruthers, Chief Financial Officer Initial Remarks Jon Congleton, President and CEO Data Highlights David
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More information22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationNOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX
Date: 14 August, 2018 Sydney, Australia ASX: NOX Noxopharm Limited NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ABN 50 608 966 123 Registered Office and Operations Office: Suite 3,
More informationASX/Media Announcement 24 December 2010
ASX/Media Announcement 24 December 2010 ANDY WELL PROJECT UPDATE Diamond drilling continues to deliver high-grade results RC drilling continues at Wilber Lode to define a JORC Resource Southern extensions
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More informationVICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06
VICAL INC FORM 8-K (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 Address 10390 PACIFIC CENTER COURT. SAN DIEGO, CA 92121-4340 Telephone 858-646-1100 CIK 0000819050 Symbol VICL SIC
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationUCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam
UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy Primary efficacy and safety data from the
More informationKorean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationCOMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing
COMPANY PRESENTATION JULY 2018 Bob Bechard Executive Vice-President Corporate Development & Licensing Forward Looking Statements Some statements in this release may contain forward-looking information.
More informationRevolutionizing how advanced heart disease is treated. Alexei Marko, CEO Chris Clark, CFO November 2014
Revolutionizing how advanced heart disease is treated Alexei Marko, CEO Chris Clark, CFO November 2014 Forward-Looking Statements Statements contained herein that are not based on historical or current
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION JUNE 2016 OTCQB:CANN ABOUT General Cannabis Corporation (GCC) is the all-in-one resource for the highest quality service providers available to the regulated Cannabis Industry. We
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More information